Top Markets
Coin of the day
Antibe Therapeutics Inc. Antibe Therapeutics Inc.

Antibe Therapeutics Inc.

ATE
Rang in aandelen #32096
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Aandeelprijs
$0.21483059
Laatst gesynchroniseerd: 2024-05-07
Marktkapitalisatie
$11.13M
Verandering (1 dag)
0.34%
Verandering (1 jaar)
0.00%
Land
CA
Handel Antibe Therapeutics Inc. (ATE)

Categorie

Aandelsplitsingen voor Antibe Therapeutics Inc. (ATE)
Het aandeel Antibe Therapeutics Inc. (symbool: ATE) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Aug 18, 2026.
Eén aandeel ATE dat vóór Aug 18, 2026 werd gekocht, staat nu gelijk aan 0 aandelen ATE.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
Bedrijf Aantal aandelen splitsingen Cumulatieve vermenigvuldiging Land
9 x285
US
9 x162
US
7 x127
IE
2 x4
US
3 x12
US